Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
Listed Suppliers
0
API
0
FDF
0
FDA Orange Book
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Brl 38705
2. Brl-38705
3. Epsiprantel, (+)-isomer
4. Epsiprantel, (-)-isomer
1. Cestex
2. 98123-83-2
3. Epsiprantel, (+)-
4. Epsiprantel, (-)-
5. Brl 38705
6. 0c1spq0fsr
7. Wuc74dw9sn
8. Ju2x6k5bl3
9. Brl38705
10. Epsiprantel (inn)
11. Brl-38705
12. Epsiprantel [inn]
13. (+-)-2-(cyclohexylcarbonyl)-2,3,6,7,8,12b-hexahydropyrazino(2,1-a)(2)benzazepin-4(1h)-one
14. Pyrazino[2,1-a][2]benzazepin-4(1h)-one, 2-(cyclohexylcarbonyl)-2,3,6,7,8,12b-hexahydro-
15. Brl38705;brl-38705;brl 38705
16. Epsiprantelum
17. (+)-2-(cyclohexylcarbonyl)-2,3,6,7,8,12b-hexahydropyrazino(2,1-a)(2)benzazepin-4(1h)-one
18. (-)-2-(cyclohexylcarbonyl)-2,3,6,7,8,12b-hexahydropyrazino(2,1-a)(2)benzazepin-4(1h)-one
19. 98123-66-1
20. 98123-67-2
21. Pyrazino(2,1-a)(2)benzazepin-4(1h)-one, 2-(cyclohexylcarbonyl)-2,3,6,7,8,12b-hexahydro-, (+)-
22. Pyrazino(2,1-a)(2)benzazepin-4(1h)-one, 2-(cyclohexylcarbonyl)-2,3,6,7,8,12b-hexahydro-, (-)-
23. Epsiprantelum [latin]
24. Epsiprantel [inn:ban]
25. Unii-0c1spq0fsr
26. Pyrazino(2,1-a)(2)benzazepin-4(1h)-one, 2-(cyclohexylcarbonyl)-2,3,6,7,8,12b-hexahydro-
27. Cestex (tn)
28. Epsiprantel [mi]
29. Unii-wuc74dw9sn
30. Unii-ju2x6k5bl3
31. 2-(cyclohexanecarbonyl)-1,3,6,7,8,12b-hexahydropyrazino[2,1-a][2]benzazepin-4-one
32. Dsstox_cid_31392
33. Dsstox_rid_97531
34. Epsiprantel [mart.]
35. Dsstox_gsid_57858
36. Chembl64979
37. Schembl165343
38. Dtxsid3057858
39. Epsiprantel [green Book]
40. Tox21_113678
41. Ncgc00249902-01
42. Cas-98123-83-2
43. D07903
44. Q1347716
45. 2-(cyclohexylcarbonyl)-4-oxo-1,2,3,4,6,7,8,12b-octahydropyrazino[2,1-a][2]benzazepine
46. (+/-)-2-(cyclohexylcarbonyl)-2,3,6,7,8,12b-hexahydropyrazino(2,1-a)(2)benzazepin-4(1h)-one
47. 2-cyclohexylcarbonyl-2,3,6,7,8,12b-hexahydropyrazino(2,1-a)(2)benzazepin-4(1h)-one
| Molecular Weight | 326.4 g/mol |
|---|---|
| Molecular Formula | C20H26N2O2 |
| XLogP3 | 3 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 1 |
| Exact Mass | 326.199428076 g/mol |
| Monoisotopic Mass | 326.199428076 g/mol |
| Topological Polar Surface Area | 40.6 Ų |
| Heavy Atom Count | 24 |
| Formal Charge | 0 |
| Complexity | 486 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Epsiprantel manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Epsiprantel, including repackagers and relabelers. The FDA regulates Epsiprantel manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Epsiprantel API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Epsiprantel supplier is an individual or a company that provides Epsiprantel active pharmaceutical ingredient (API) or Epsiprantel finished formulations upon request. The Epsiprantel suppliers may include Epsiprantel API manufacturers, exporters, distributors and traders.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Epsiprantel as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Epsiprantel API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Epsiprantel as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Epsiprantel and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Epsiprantel NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Epsiprantel suppliers with NDC on PharmaCompass.
Epsiprantel Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Epsiprantel GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Epsiprantel GMP manufacturer or Epsiprantel GMP API supplier for your needs.
A Epsiprantel CoA (Certificate of Analysis) is a formal document that attests to Epsiprantel's compliance with Epsiprantel specifications and serves as a tool for batch-level quality control.
Epsiprantel CoA mostly includes findings from lab analyses of a specific batch. For each Epsiprantel CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Epsiprantel may be tested according to a variety of international standards, such as European Pharmacopoeia (Epsiprantel EP), Epsiprantel JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Epsiprantel USP).
LOOKING FOR A SUPPLIER?
